Interferon‐Driven Biomarkers and Synergistic Therapy for PRMT5 Inhibition in Triple‐Negative Breast Cancer
Advanced Science · 2026-01 · 13 (6)
DOI: 10.1002/advs.202505787 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 19.11.2025. Verfasst von Ziwen Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Cancer Hospital, Division of Breast Cancer, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, C…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Protein-Arginine N-Methyltransferases, Interferons, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation, Zhejiang Provincial Key R&D Program.
Abstract (Originalsprache)
Triple‐negative breast cancer (TNBC) exhibits heterogeneous responses to PRMT5 inhibition, posing challenges for therapeutic targeting. Here, using PRMT5 inhibitors, coupled with transcriptomic profiling, basal interferon (IFN) signaling is identified as a biomarker of PRMT5 inhibition sensitivity. Sensitive TNBC models are characterized by elevated DNA damage, which correlated with enriched IFN pathway activity. Pharmacologically inducing DNA damage with the PARP inhibitor Olaparib activated IFN signaling and synergistically sensitized resistant TNBC cells to PRMT5 inhibition. Comprehensive pre‐clinical validation in patient‐derived organoid (PDO) and xenograft (PDX) models demonstrated robust antitumor efficacy of this combination therapy. Moreover, this dual targeting strategy reshaped the tumor microenvironment, enhancing dendritic cell‐CD8 + T cell crosstalk and conferring durable antitumor immunity in vivo. This study establishes IFN‐driven transcriptional signatures as predictive biomarkers for PRMT5 inhibitor response and unveils a rational combination strategy to overcome resistance in TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhejiang Cancer Hospital, Division of Breast Cancer, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
- School of Life Sciences, Tianjin University, Tianjin, 300072, China.
- Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, China.
ORCID-Profile: Qin Wu
Förderung
- National Natural Science Foundation of China
- Zhejiang Provincial Natural Science Foundation
- Zhejiang Provincial Key R&D Program
- Zhejiang Provincial Medical and Health Science and Technology Program
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Zhang, Z., Zhang, S., Guo, L., Pan, Y., Huang, J., Ji, Y., Tao, J., Wei, Y., Wang, X., & Wu, Q. (2026). Interferon‐Driven Biomarkers and Synergistic Therapy for PRMT5 Inhibition in Triple‐Negative Breast Cancer. Advanced Science, 13(6). https://doi.org/10.1002/advs.202505787
Vancouver
Zhang Z, Zhang S, Guo L, Pan Y, Huang J, Ji Y, et al. Interferon‐Driven Biomarkers and Synergistic Therapy for PRMT5 Inhibition in Triple‐Negative Breast Cancer. Advanced Science. 2026;13(6). doi:10.1002/advs.202505787
BibTeX
@article{Zhang2026,
author = {Zhang, Ziwen and Zhang, Sheyu and Guo, Lu and Pan, Yichun and Huang, Juan and Ji, Yishuai and Tao, Jiaqi and Wei, Yong and Wang, Xiaojia and Wu, Qin},
title = {Interferon‐Driven Biomarkers and Synergistic Therapy for PRMT5 Inhibition in Triple‐Negative Breast Cancer},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {6},
doi = {10.1002/advs.202505787}
}
EUVIMED